the Efficacy and Safety of Oliceridine Fumarate Injection for Acute Pain After Abdominal Surgery: a Randomized, Double-blind, Positive-drug Parallel-controlled, Multi-center Clinical Study

The goal of this clinical trial is to learn if Oliceridine fumarate injection works to treat acute pain after abdominal surgery. It will also learn about the safety of Oliceridine fumarate injection. The main questions it aims to answer are:
1. Does Oliceridine fumarate injection works to treat acute pain after abdominal surgery?
2. Does Oliceridine fumarate injection lead to less adverse effect?
Researchers will compare Oliceridine fumarate injection to a positive-drug (Sufentanil Citrate) to see if Oliceridine fumarate injection not inferior to sufentanil in the efficacy and safety for acute pain after abdominal surgery.
Participants will:
1. Receive patient controlled analgesia treat using Oliceridine or sufentanil after surgery
2. Be followed up every 6 hours until 48 hours after surgery or before discharge

Start Date01 Aug 2024

Sponsor / Collaborator

Xiangya Hospital Central South University

NCT06388408 / CompletedNot ApplicableIIT

Effects of Sufentanil Delivered With Target Controlled Infusion (TCI) on Patient State Index Values, Electroencephalographic Spectrum and Analgesia Nociception Index During Total Intravenous Anesthesia With Propofol TCI

Sufentanil Target Controlled infusion (TCI, Gepts model) effects on Neuromonitoring during Total Intravenous Anesthesia (TIVA) with Propofol TCI (Eleveld model) has not been investigate yet.
Authors aim to investigate its effect on Patient State index (PSi), the power spectrum EEG, the Analgesia Nociception Index (ANI) nad pupillometry values during maintenance durin TIVA-TCI with Propofol and Sufentanil.

Start Date05 May 2024

Sponsor / Collaborator

University of Padua

NCT05957653 / Not yet recruitingPhase 4IIT

Lidocaine Combined With Sufentanil for Preventing Catheter-related Bladder Discomfort After Robot-assisted Radical Prostatectomy: a Randomized, Double-blind, Controlled Trial

The goal of this clinical trial is to evaluate the incidence and severity of postoperative catheter-related bladder discomfort after robot-assisted radical prostatectomy.
The main question it aims to answer is to evaluate incidence of CRBD immediately after extubation in resuscitation.
A total of 20ml of 2% lidocaine and 1μg/ml sufentanil or 20ml normal saline was injected into the bladder of the participants through the catheter. After drug injection, the catheter was clamped for 20 minutes, and then 100ml normal saline was injected into the bladder through the catheter to flush out.
Then, the incidence of CRBD was compared between the two groups.

Start Date07 Oct 2023

Sponsor / Collaborator

Shanghai Renji Hospital

100 Clinical Results associated with Sufentanil Citrate

100 Translational Medicine associated with Sufentanil Citrate

100 Patents (Medical) associated with Sufentanil Citrate

Literatures (Medical) associated with Sufentanil Citrate

10 Apr 2024·Videosurgery and Other Miniinvasive Techniques

Comparison of low and standard pneumoperitoneum pressure in laparoscopic pediatric inguinal hernia repair

Article

Author: Lyu, Yunxiao ; Chen, Liang

Introduction:

The effectiveness and safety of low pneumoperitoneum in laparoscopic pediatric inguinal hernia repair is unclear and required to explore.

Aim:

To evaluate the benefits of low (LPP) vs. standard pneumoperitoneum pressure (SPP) in laparoscopic pediatric inguinal hernia repair.

Material and methods:

We performed a retrospective cohort analysis of patients with pediatric inguinal hernia. The patients were divided into LPP and SPP groups. Anesthesia and postoperative characteristics were analyzed.

Results:

We enrolled 169 eligible patients in this study. Anesthesia and postanesthesia care unit times in the LPP group were lower than those in the SPP group (p = 0.00, p = 0.01, respectively). The LPP group had lower values for peak partial pressure of end-tidal carbon dioxide (P_ETCO₂; mm Hg) (33.37 ±4.09 vs. 36.56 ±4.08), trough P_ETCO₂ (38.33 ±5.04 vs. 40.46 ±4.14), and P_ETCO₂ at the end of surgery (35.29 ±4.59 vs. 38.76 ±4.22). The LPP group required less sufentanil citrate (8.76 ±4.07 ml vs. 18.03 ±16.04 ml) and midazolam (1.56 ±0.45 ml vs 1.79 ±0.59 ml) vs. the SPP group, respectively. There was no significant difference between the groups regarding postoperative complications.

Conclusions:

LPP was associated with shorter anesthesia and postanesthesia care unit times, and lower P_ETCO₂ values compared with SPP. Compared with the SPP group, the LPP group had comparable operation times and postoperative complications. However, long-term outcome studies are needed.

12 Jan 2024·Zhongguo zhen jiu = Chinese acupuncture & moxibustion

Effect of acupuncture at Shuitong and Shuijin points on sufentanil-induced cough in general anesthesia induction: a randomized controlled trial.

Article

Author: Xu, Jiping ; Li, Peng ; Ji, Jiafu ; Su, Fan ; Hu, Lihua

OBJECTIVES:

To observe the therapeutic effect of acupuncture at Shuitong and Shuijin points on preventing sufentanil-induced cough and its influence on hemodynamics in general anesthesia induction.

METHODS:

A total of 80 patients scheduled for elective surgery undergoing general anesthesia were randomly divided into an observation group (40 cases) and a control group (39 cases,1 case eliminated). In the control group, the routine anesthesia was performed,with intravenous injection of 1% sufentanil citrate 0.5 μg/kg, 1% propofol (total amount was calculated according to 2 mg/kg) and cisatracurium besilate 0.2 mg/kg. In the observation group, before routine anesthesia induction, acupuncture was applied to Shuitong and Shuijin points on the right and the needles were retained for 30 min. During anesthesia induction, the complications i.e. cough and chest wall stiffness were observed, and the systolic blood pressure (SBP), heart rate (HR) and pulse oxygen saturation (SpO₂) were monitored 5 min after the patients entered the operation room (T₀),at the moment of intravenous injection of sufentanil (T₁) and 2 min after sufentanil injection (T₂) , 1 min before and after endotracheal intubation (T₃,T₄) of the two groups, respectively.

RESULTS:

During anesthesia induction,the condition of mild, moderate and severe cough in the observation group was superior to that of the control group (P<0.05), the total cases of cough and its total incidence were lower than those of the control group (P<0.05). Two cases of chest wall stiffness were present in each group, but without statistical difference between the two groups (P>0.05). In comparison of SBP, HR and SpO₂ at T₀, T₁, T₂, T₃ and T₄, the differences were not significant statistically between the two groups (P>0.05). SBP and HR increased at T₂ when compared with those at T₁ in the control group (P<0.05), but there was no statistical difference in SpO₂ (P>0.05); while, the differences in SBP, HR and SpO₂ were not significant at T₂ when compared with those at T₁ in the observation group (P>0.05).

CONCLUSIONS:

Acupuncture at Shuitong and Shuijin points can effectively prevent from sufentanil-induced cough, reduce the severity of cough and stabilize the hemodynamic indicators.

01 May 2023·Applied spectroscopy

Quantitative Raman Cross-Sections and Band Assignments for Fentanyl and Fentanyl Analogs

Article

Author: Kline, Neal D. ; Wilcox, Phillip G. ; Pardoe, Ian J. ; Emmons, Erik D. ; Guicheteau, Jason A.

Raman cross sections and spectra were measured for five synthetic opioid fentanyl analogs: fentanyl citrate, sufentanil citrate, alfentanil HCl, carfentanil oxalate, and remifentanil HCl. The measurements were performed with excitation wavelengths in the visible (532 nm) and near infrared (785 nm). In addition, density functional theory (DFT) calculations were employed to generate simulated spectra of the compounds and aid in identification of the observed spectral modes. These cross-section measurements and calculations were also used to assess results from a series of measurements of fentanyls cut with other powdered materials. These measurements are valuable for assessment of field-deployable Raman chemical sensors for detection of fentanyl and fentanyl analogs, including when mixed with other materials.

News (Medical) associated with Sufentanil Citrate

23 Sep 2024

·www.globenewswire.com

Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)

MIPLYFFA™ is the first therapy approved for use in patients with NPC, a rare genetic disorder XOMA Royalty is entitled to receive a mid-single digit royalty on MIPLYFFA™ sales and up to $52.6 million in milestones MIPLYFFA™ is now the sixth commercial asset in XOMA Royalty’s portfolio EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today Zevra Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for MIPLYFFA™ (arimoclomol). MIPLYFFA™ is approved for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients two years of age and older. It is the sixth commercial asset in XOMA Royalty’s growing royalty and milestone portfolio. “With the approval of MIPLYFFA™, NPC patients in the United States now have access to the first FDA approved therapeutic in this rare, progressive and fatal neurodegenerative disease,” stated Owen Hughes, Chief Executive Officer of XOMA Royalty. “Based on the clinical data to date, we believe MIPLYFFA™ plus miglustat has the potential to improve outcomes and slow disease progression for many NPC patients.” In June 2023, XOMA Royalty announced it had paid LadRx a $5 million upfront payment plus a share of future event-based milestones to acquire a mid-single digit royalty on arimoclomol’s commercial sales and up to $52.6 million, net, in potential milestone payments from Zevra. About XOMA Royalty CorporationXOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial therapeutic candidates and commercial assets that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio with more than 70 assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn. Forward-Looking Statements/Explanatory Notes Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the amount of potential milestone and commercial payments to XOMA Royalty and other developments related to MIPLYFFA™ (arimoclomol), and the potential of XOMA Royalty’s portfolio of partnered programs and licensed technologies generating substantial milestone and royalty proceeds over time. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. These forward-looking statements are not a guarantee of XOMA Royalty’s performance, and you should not place undue reliance on such statements. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; if the therapeutic product candidates to which we have a royalty interest do not receive regulatory approval, and our third-party licensees will not be able to market them. Other potential risks to XOMA Royalty meeting these expectations are described in more detail in XOMA Royalty's most recent filing on Form 10-Q and in other filings with the Securities and Exchange Commission. Consider such risks carefully when considering XOMA Royalty's prospects. Any forward-looking statement in this press release represents XOMA Royalty's beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA Royalty disclaims any obligation to update any forward-looking statement, except as required by applicable law. EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development. As of the date of this press release, the commercial assets in XOMA Royalty’s milestone and royalty portfolio are VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), MIPLYFFA™ (arimoclomol), XACIATO™ (clindamycin phosphate) vaginal gel 2%, IXINITY® [coagulation factor IX (recombinant)], and DSUVIA® (sufentanil sublingual tablet). All other assets in the milestone and royalty portfolio are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available. Investor Contact Media ContactJuliane SnowdenKathy VincentXOMA Royalty CorporationKV Consulting & Management+1 646-438-9754+1 310-403-8951juliane.snowden@xoma.comkathy@kathyvincent.com

Drug Approval

23 Sep 2024

·www.globenewswire.com

XOMA Royalty Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA’s 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share. The preferred dividends will be paid on or about October 15, 2024, to respective holders of record at the close of business on October 3, 2024. About XOMA Royalty CorporationXOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial therapeutic candidates and commercial assets that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio with more than 70 assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn. EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development. As of the date of this press release, the commercial assets in XOMA Royalty’s milestone and royalty portfolio are VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), MIPLYFFA™ (arimoclomol), XACIATO™ (clindamycin phosphate) vaginal gel 2%, IXINITY® [coagulation factor IX (recombinant)], and DSUVIA® (sufentanil sublingual tablet). All other assets in the milestone and royalty portfolio are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available. Investor ContactJuliane SnowdenXOMA Royalty Corporation+1 646-438-9754juliane.snowden@xoma.comMedia ContactKathy VincentKV Consulting & Management+1 310-403-8951kathy@kathyvincent.com

08 Aug 2024

·www.echemi.com

Humanwell Healthcare Reports 3.86% Revenue Growth in H1 2024

The latest release shows that Humanwell Healthcare has delivered remarkable results in the first half of 2024, demonstrating excellent market performance. Specifically, the company managed to achieve solid growth in total operating revenue, totaling RMB12.861 billion, an increase of 3.86% over the same period last year, marking the fourth consecutive year of good growth for Humanwell Healthcare. Despite some fluctuations in net profit, Humanwell Healthcare's core subsidiary, Yichang Humanwell, maintained strong growth momentum and achieved double-digit growth rates, providing strong support for the company's overall performance. As a leading pharmaceutical company in China, Humanwell Healthcare has been committed to the research and development, production and sales of pharmaceutical products since its establishment in 1993. Headquartered in Wuhan, Hubei Province, Humanwell Healthcare is a key player in China's pharmaceutical industry. Humanwell Healthcare's product line is rich and diverse, including many star products. Compound Cloloterol propionate tablet, as one of the company's core products, is an oral drug for type 2 diabetes, which has the effect of significantly reducing blood sugar and protecting islet function, and enjoys a high reputation in the field of diabetes treatment in China. Gastrodine capsule is a Chinese medicine preparation for the treatment of ischemic stroke sequelae, which can significantly improve the blood supply to the brain and promote the repair of nerve function, and is an important representative of the company in the field of Chinese medicine. In addition, as the company's main product in the field of respiratory treatment, trimebutin tablets can effectively improve the respiratory function of patients with chronic obstructive pulmonary disease (COPD), and occupy an important position in the domestic COPD treatment market. Humanwell Healthcare continues to consolidate and expand its market leadership in the key area of neurological medicine. The company's two star narcotic products - remifentanil hydrochloride for injection and sufentanil citrate injection, the performance of the national hospital market in 2023 is particularly eye-catching. The combined sales of these two products reached 6.778 billion yuan, accounting for more than 40% of the market share. Among them, remifentanil hydrochloride for injection is as high as 90.28% of the market share, sitting firmly on the throne of "anesthesia first", its market position is rock-solid. Humanwell Healthcare will continue to uphold the philosophy of continuous innovation and excellence to further consolidate its leading position in the field of anesthetics. At the same time, the company will also accelerate the research and development process of new product pipelines, actively expand other therapeutic areas, and continuously improve its overall competitive strength with a diversified product portfolio and strong research and development strength. We firmly believe that with the joint efforts of all employees, Humanwell Healthcare will be able to create even more brilliant results and bring even greater returns to shareholders.

Drug Approval

100 Deals associated with Sufentanil Citrate

External Link

KEGG	Wiki	ATC	Drug Bank
D00845	Sufentanil Citrate	N01AH03	DB00708

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acute Pain	US	Vertical Pharmaceuticals LLC	02 Nov 2018
Pain	EU	Laboratoire Aguettant SAS	25 Jun 2018
Pain	IS	Laboratoire Aguettant SAS	25 Jun 2018
Pain	LI	Laboratoire Aguettant SAS	25 Jun 2018
Pain	NO	Laboratoire Aguettant SAS	25 Jun 2018
Pain, Postoperative	EU	FGK Representative Service GmbH	18 Sep 2015
Pain, Postoperative	IS	FGK Representative Service GmbH	18 Sep 2015
Pain, Postoperative	LI	FGK Representative Service GmbH	18 Sep 2015
Pain, Postoperative	NO	FGK Representative Service GmbH	18 Sep 2015
Anesthesia	US	Rising Pharmaceuticals, Inc.Startup	04 May 1984
Vaginal delivery procedure	US	Rising Pharmaceuticals, Inc.Startup	04 May 1984

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Pain	Phase 1	CN	Yichang Humanwell Pharmaceuticals Co., Ltd.	08 Mar 2023
Analgesia	IND Approval	CN	Yichang Humanwell Pharmaceuticals Co., Ltd.	23 Jul 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04959812 (CTgov)	Phase 1/2	Hemorrhage	46	sufentanil (Sufentanil)	fqjpmsvori(rtiybmakvp) = ruzrmygqsq tnepyytgbi (urwczlavlt, qnfqibnsyd - fmpndvmabz) View more	-	11 Jul 2024
				Placebo (Placebo)	fqjpmsvori(rtiybmakvp) = wykrvvkvqc tnepyytgbi (urwczlavlt, cdijldtyuj - fzpxocajee) View more
NCT04561375 (CTgov)	Phase 4	-	61	Sufentanil (Intervention Group)	rspbtdnmry(fajnuxlkrp): Proportional odds ratio = 0.37 (95% CI, 0.13 - 1.07), P-Value = 0.067 View more	-	13 Dec 2023
				Fentanyl (Control Group)
NCT02989597 (MAPS, CTgov)	Phase 4	Pain, Postoperative	10	Spinal Fusion Surgery+Sufentanil+Methadone Hydrochloride+Dexamethasone+ketamine+Remifentanil (Intra-operative Methadone Hydrochloride)	mcqapyvyrp(twxjtzbkmh) = yrfozfsibc inyqjtvwdj (odyzsvinqo, ixsvkocglb - fblurjdjoh) View more	-	25 Apr 2023
				Spinal Fusion Surgery+Sufentanil+Dexamethasone+ketamine+Remifentanil (Control)	mcqapyvyrp(twxjtzbkmh) = ubbkcyhkrn inyqjtvwdj (odyzsvinqo, fcuenmbapm - aqnhyqmrrx) View more
NCT04226495 (CTgov)	Phase 4	Anesthesia	64	Sufentanil Bolus (Sufentanil Bolus)	ossmvsrbqr(vzmlkegyev) = icfhafrlud syqlfbusua (pallslzgzj, dsjbsjsdls - nbjqygrcew) View more	-	28 Feb 2023
				Sufentanil Infusion (Sufentanil Infusion)	ossmvsrbqr(vzmlkegyev) = atuvxulwcu syqlfbusua (pallslzgzj, ybwcyklzsv - nanzhdcniy) View more
Pubmed	Not Applicable	Heart Diseases	-	Opioid-balanced general anesthesia with lidocaine	udnefwrosy(jehpzpqgwj): OR = 0.72 (95% CI, 0.58 - 0.92)	Positive	10 Feb 2023
				Nonopioid-balanced general anesthesia
NCT02573597 (CTgov)	Phase 4	Pregnancy \| Duration of labor \| Labor Pain	31	sufentanil+Bupivacaine (Part A Group 1)	hpsduyuwsa(plwghoohpm) = ewolrylkme cyxhlpqmjb (yaslocsfpg, sxwinbqlrv - bouwbacusd) View more	-	18 Oct 2022
				sufentanil+Bupivacaine (Part A Group 2)	hpsduyuwsa(plwghoohpm) = xhmungaqqv cyxhlpqmjb (yaslocsfpg, kptqhqnzyq - acajttczak) View more
NCT04177862 (CTgov)	Phase 4	Anesthesia \| Acute Pain	75	Sublingual Sufentanil (Sublingual Sufentanil)	khgralsyuz(tldauipfeq) = mmntazlqwk mxxyvxxgpp (umdbmbmapa, lkkwpgrqgy - oenbxjhgvj) View more	-	02 Feb 2021
				IV Fentanyl (IV Fentanyl)	khgralsyuz(tldauipfeq) = tsbuihawqs mxxyvxxgpp (umdbmbmapa, exfmfemjzo - clfolxgwnl) View more
NCT02662764 (CTgov)	Phase 3	Acute Pain	320	Zalviso™ 15 mcg	mzbgcqnoil(vlozvqmtlx) = gxjvgixkgs qrgijchpbf (sebkdtktky, mecgnabvdt - cudxmwgpba) View more	-	08 Aug 2018
NCT01012999 (CTgov)	Phase 1/2	Pain \| Limb injury	16	sufentanil	jdslilhjwm(yiopcmrlbo) = gfaopzkuwd nqmuonbcbc (lxgbledgrp, xmcmgszcfu - ucjtnbtrbp) View more	-	22 Jun 2017
NCT02430090 (CTgov)	Phase 2	Anesthesia	45	Levobupivacaine (Levobupivacaine)	dbekibwagz(sabapdawzp) = dpdmdufakx selmdiggcr (zamkrjbhrm, fkmfgvzlcs - nknpjjdnyg) View more	-	10 Jun 2015
				Levobupivacaine+fentanyl (Levobupivacaine + Fentanyl)	dbekibwagz(sabapdawzp) = xvnoarxggr selmdiggcr (zamkrjbhrm, lfhrceyazh - adptaboacm) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis